Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
(Redirected from IMPA1)
Protein-coding gene in the species Homo sapiens
Inositol monophosphatase 1 is an enzyme that in humans is encoded by the IMPA1gene.
Interacting partners
IMPA1 has been shown to interact with Bergmann glial S100B and calbindin.
Chemical inhibitors
L-690,330 is a competitive inhibitor of IMPase activity with very good activity in vitro however with limited bioavailabilityin vivo. Due to its increased specificity compared to Lithium, L-690,330 has been used extensively in characterizing the results of IMPase inhibition in various cell culture models. L-690,488, a prodrug or L-690,330, has also been developed which has greater cell permeability. Treatment of cortical slices with L-690,488 resulted in accumulation of inositol demonstrating the activity of this inhibitor in tissue.
Initially it was noticed that several drugs useful in treatment of bipolar disorder such as lithium, carbamazepine and valproic acid had a common mechanism of action on enzymes in the phosphatidylinositol signalling pathway and the inositol depletion hypothesis for the pathophysiology of bipolar disorder was suggested. Intensive research has so far not confirmed this hypothesis, partly because lithium can also act on a number of other enzymes in this pathway, complicating results from in vitro studies.
Atack JR, Cook SM, Watt AP, Fletcher SR, Ragan CI (February 1993). "In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330". J. Neurochem. 60 (2): 652–8. doi:10.1111/j.1471-4159.1993.tb03197.x. PMID8380439. S2CID23498954.
Atack JR, Prior AM, Fletcher SR, Quirk K, McKernan R, Ragan CI (July 1994). "Effects of L-690,488, a prodrug of the bisphosphonate inositol monophosphatase inhibitor L-690,330, on phosphatidylinositol cycle markers". J. Pharmacol. Exp. Ther. 270 (1): 70–6. PMID8035344.
Bone R, Frank L, Springer JP, Pollack SJ, Osborne S, Atack JR, Knowles MR, McAllister G, Ragan CI (1994). "Structural analysis of inositol monophosphatase complexes with substrates". Biochemistry. 33 (32): 9460–9467. doi:10.1021/bi00198a011. PMID8068620.
Bone R, Frank L, Springer JP, Atack JR (1994). "Structural studies of metal binding by inositol monophosphatase: evidence for two-metal ion catalysis". Biochemistry. 33 (32): 9468–9476. doi:10.1021/bi00198a012. PMID8068621.
Ganzhorn AJ, Lepage P, Pelton PD, Strasser F, Vincendon P, Rondeau JM (1996). "The contribution of lysine-36 to catalysis by human myo-inositol monophosphatase". Biochemistry. 35 (33): 10957–10966. doi:10.1021/bi9603837. PMID8718889.
Parthasarathy L, Parthasarathy R, Vadnal R (1997). "Molecular characterization of coding and untranslated regions of rat cortex lithium-sensitive myo-inositol monophosphatase cDNA". Gene. 191 (1): 81–87. doi:10.1016/S0378-1119(97)00045-0. PMID9210592.
Sjøholt G, Molven A, Løvlie R, Wilcox A, Sikela JM, Steen VM (1997). "Genomic structure and chromosomal localization of a human myo-inositol monophosphatase gene (IMPA)". Genomics. 45 (1): 113–122. doi:10.1006/geno.1997.4862. PMID9339367.
Nemanov L, Ebstein RP, Belmaker RH, Osher Y, Agam G (1999). "Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels". The International Journal of Neuropsychopharmacology. 2 (1): 25–29. doi:10.1017/S1461145799001315. PMID11281967. S2CID16964945.
Atack JR, Schapiro MB (2002). "Inositol monophosphatase activity in normal, Down syndrome and dementia of the Alzheimer type CSF". Neurobiol. Aging. 23 (3): 389–396. doi:10.1016/S0197-4580(01)00335-9. PMID11959401. S2CID24701473.
Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M (2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature. 437 (7062): 1173–1178. Bibcode:2005Natur.437.1173R. doi:10.1038/nature04209. PMID16189514. S2CID4427026.